Summary Advaxis stock has recently quadrupled from $3 to as high as $13. Management has a history of promotional and misleading activities, including heavy use of the Dream Team Group. Tumor response data for its lead candidate has been mis-presented to overstate effectiveness. ADXS-HPV has demonstrated notably inferior survival rates vs. alternatives. Over 3 million…

Read More